Study shows encouraging therapeutic options for patients with relapsed multiple myeloma

Diabetes May Accelerate Blood Cancer Growth, Yet Survival Outcomes Differ by Race

Potential Treatment Options for Patients With Relapsed Multiple Myeloma Following CAR T-Cell Therapy

Myeloma Patients Who Relapse After CAR T-Cell Therapy Have Options

Researchers Find Treatment Options for Patients Whose Blood Cancer Relapses After CAR-T

Mount Sinai Researchers Report Encouraging Immunotherapy Option for Relapsed Myeloma Patients

Study Identifies Three-Gene Signature That May Predict Response to Selinexor in Patients With Multiple Myeloma

Blood-Based PD-L1 Tracking Could Offer Improved Response Prediction for Lung Cancer Immunotherapy

Third Dose of COVID-19 Vaccine Significantly Increases Immune Responses in Most Patients With Multiple Myeloma

Potentially Serious Side Effect Seen in Patient after Immunotherapy

Cancer Patients With Poor Antibody Response to COVID-19 Vaccines Also Lack Secondary Immune Response, Study Shows